

ARTESIA a NOAH-AFNET-6


Dan Wichterle

Klinika kardiologie IKEM

- Léčba NOAC je prospěšná pro většinu pacientů s fibrilací síní
- Je také prospěšná pro pacienty se „subklinickou“ fibrilací síní?

„subklinická“ fibrilace síní

atrial high rate episodes



device-detected atrial fibrillation

ORIGINAL ARTICLE

Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

P. Kirchhof, T. Toennis, A. Goette, A.J. Camm, H.C. Diener, N. Becher, E. Bertaglia, C. Blomstrom Lundqvist, M. Borlich, A. Brandes, N. Cabanelas, M. Calvert, G. Chlouverakis, G.-A. Dan, J.R. de Groot, W. Dichtl, B. Kravchuk, A. Lubiński, E. Marijon, B. Merkely, L. Mont, A.-K. Ozga, K. Rajappan, A. Sarkozy, D. Scherr, R. Sznajder, V. Velchev, D. Wichterle, S. Sehner, E. Simantirakis, G.Y.H. Lip, P. Vardas, U. Schotten, and A. Zapf, for the NOAH-AFNET 6 Investigators*

N = 2536
EDOxabAN

Circulation

ORIGINAL RESEARCH ARTICLE

Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials

William F. McIntyre¹, MD, PhD; Alexander P. Benz², MD, MSc; Nina Becher³, MD; Jeffrey S. Healey⁴, MD, MSc; Christopher B. Granger⁵, MD; Lena Rivard⁶, MD, MSc; A. John Camm⁷, MD; Andreas Goette⁸, MD; Antonia Zapf⁹, PhD; Marco Alings¹⁰, MD, PhD; Stuart J. Connolly¹¹, MD, MSc; Paulus Kirchhof¹², MD; Renato D. Lopes¹³, MD, MHS, PhD

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JANUARY 11, 2024


VOL. 390 NO. 2

Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation


J.S. Healey, R.D. Lopes, C.B. Granger, M. Alings, L. Rivard, W.F. McIntyre, D. Atar, D.H. Birnie, G. Boriani, A.J. Camm, D. Conen, J.W. Erath, M.R. Gold, S.H. Hohnloser, J. Ip, J. Kautzner, V. Kutlyifa, C. Linde, P. Mabo, G. Mairesse, J. Benezet Mazuecos, J. Cosedis Nielsen, F. Philippon, M. Proietti, C. Sticherling, J.A. Wong, D.J. Wright, I.G. Zarraga, S.B. Coutts, A. Kaplan, M. Pombo, F. Ayala-Paredes, L. Xu, K. Simek, S. Nevills, R. Mian, and S.J. Connolly, for the ARTESiA Investigators*

N = 4012
APIxabAN


A Stroke, Systemic Embolism, or Death from Cardiovascular Causes



B Major Bleeding or Death from Any Cause



Stroke or Systemic Embolism




Major Bleeding


HR: 1.80 [1.26-2.57]

Meta-analysis: ARTESIA & NOAH-AFNET-6


Ischemic Stroke




Major Bleeding



Any stroke, systemic/pulmonary embolism, MI, CV death




All-Cause Death or Major Bleeding




Meta-analysis: ARTESIA & NOAH-AFNET-6

Cardiovascular Death



All-Cause Death



- Léčba NOAC u pacientů s fibrilací síní detekovanou jen implantovanými přístroji:
 - **snižuje výskyt ischemické CMP o 32%**
 - **zvyšuje výskyt závažného krvácení o 62%**
 - **neovlivňuje mortalitu**